FDA Approves First-of-Its-Kind FluMist Nasal Spray for Self-Administration

Sep 20, 2024, 08:15 PM

The U.S. Food and Drug Administration (FDA) has approved AstraZeneca's FluMist nasal spray influenza vaccine for self-administration, making it the first of its kind. This approval marks the first time a flu vaccine can be administered at home without the need for a healthcare provider. The FluMist vaccine, which contains a weakened live virus, is designed for individuals aged 2 to 49 and covers influenza virus subtypes A and B. This development is part of a broader effort by the FDA to expand consumer access to medicines and reduce healthcare costs and barriers. The vaccine will be available through a third-party pharmacy, where individuals will complete a screening and eligibility assessment before ordering. The FluMist nasal spray will be available starting next season.